It won't because the problem with regenerative medicine is that if they actually work they will bankrupt the government and the health insurance industry.
Look at the $450k a pop immunotherapy that was just approved and was developed using tax payer money. Imagine when the industry matures and every therapy is looking for $500k a pop? Medicare bankrupt, health insurance premiums will go up.
ENDV's therapies are scalable like making iPhones, the more you make the less they cost. The non-invasive nature can also help make clinical trials shorter and less expensive.
News 
Market Data 
Discover 
